. 2017 Apr 21;12(4):e0176379. doi: 10.1371/journal.pone.0176379

Table 3. MIC distribution and frequency of resistance (%R) among clinical Staphylococcus aureus isolated from horses (n = 53), dogs (n = 47), and cats (n = 17) in Australia^b.

Antimicrobials	Animals	% R	95% CI	Percentage of isolates with indicated MIC^a
Antimicrobials	Animals	% R	95% CI	≤0.004	0.008	0.016	0.03	0.06	0.13	0.25	0.5	1	2	4	8	16	32	≥64
Amikacin	Horse	9.4	3.1–20.7							1.9	1.9	3.8	43.4	24.5	15.1	7.5	1.9
	Dog	2.1	0.1–11.3							2.1	2.1	6.4	36.2	46.8	4.3	2.1
	Cat	0	0.0–19.5										58.8	41.2
Amoxicillin-clavulanate	Horse (SSTI)	47.2	33.7–60.5						9.4	22.6	20.8	17	3.8	9.4	3.8	1.9	11.3
	Dog (SSTI)	59.5	43.3–74					7.1		14.3	19.1	9.5	14.3	19.1	2.4		14.3
	Dog (UTI)	0	0–0.5							60		40
	Cat	58.8	35.4–82.2					11.8		5.9	23.5	29.4	17.6				11.8
Cefovecin	Horse	13.2	5.5–25.3						3.8	3.8	7.5	66	5.7	1.9				11.3
	Dog	14.9	6.2–28.3					2.1	12.8	6.4	12.8	51.1			2.1			12.8
	Cat	17.6	3.8–43.4							5.9	35.3	41.2						17.6
Cefoxitin	Horse	11.3	4.3–23.0						3.8	3.8	1.9	3.8	43.4	32.1			5.7	5.7
	Dog	12.8	4.8–25.7						10.6	10.6	2.1	4.3	38.3	21.3		2.1	2.1	8.5
	Cat	17.6	3.8–43.4										29.4	52.9			5.9	11.8
Ceftriaxone	Horse	13.2	5.5–25.3							1.9	1.9	9.4	15.1	58.5		1.9	11.3
	Dog	12.8	4.8–25.7							2.1	8.5	12.8	17	46.8			12.8
	Cat	17.6	3.8–43.4									5.9	52.9	23.5			17.6
Cephalothin	Horse	11.3	4.3–23.0					5.7	3.8	35.8	32.1	9.4		1.9			5.7	5.7
	Dog	12.8	4.8–25.7					12.8	12.8	8.5	38.3	14.9			4.3			8.5
	Cat	11.8	1.5–36.4						5.9	17.6	41.2	17.6	5.9					11.8
Chloramphenicol	Horse	1.9	0.0–10.1											15.1	83			1.9
	Dog	2.1	0.1–11.3									2.1		25.5	70.2			2.1
	Cat	0	0.0–19.5											5.9	94.1
Ciprofloxacin	Horse	1.9	0.0–10.1					15.1	37.7	39.6	5.7				1.9
	Dog	8.5	2.4–20.4					4.3	27.7	29.8	27.7	2.1			8.5
	Cat	11.8	1.5–36.4							64.7	23.5				11.8
Clindamycin	Horse	0	0.0–10.1					20.8	77.4		1.9
	Dog	2.1	0.5–14.5				2.1	34	59.6		2.1						2.1
	Cat	0	0.0–19.5					47.1	52.9
Enrofloxacin	Horse	1.9	0.0–10.1				1.9	32.1	54.7	9.4					1.9
	Dog	8.5	2.4–20.4				2.1	8.5	53.2	23.4	2.1	2.1			8.5
	Cat	11.8	1.5–36.4					11.8	52.9	23.5					11.8
Marbofloxacin	Horse	1.9	0.0–10.1					1.9	1.9	75.5	18.9				1.9
	Dog	8.5	2.4–20.4					2.1	4.3	40.4	40.4	4.3			8.5
	Cat	11.8	1.5–36.4							29.4	58.8				11.8
Oxacillin	Horse	11.3	4.3–23.0						17	37.7	30.2	3.8					1.9	9.4
	Dog	12.8	4.8–25.7					2.1	21.3	14.9	44.7	2.1	2.1				4.3	8.5
	Cat	17.6	3.8–43.4						11.8	23.5	47.1			5.9				11.8
Pradofloxacin	Horse	1.9	2.4–20.4			13.2	52.8	30.2			1.9		1.9
	Dog	8.5	2.4–20.4			4.3	17	46.8	23.4					6.4	2.1
	Cat	11.8	1.5–36.4			5.9	17.6	64.7					5.9	5.9
Rifampicin	Horse	9.4	3.1–20.7	45.3	43.4	1.9								9.4
	Dog	0	0.0–7.5	53.2	44.7			2.1
	Cat	0	0.0–19.5	35.3	64.7
Tetracycline	Horse	32.1	19.9–46.3						30.2	28.3	9.4		1.9		1.9		5.7	22.6
	Dog	10.6	3.5–23.1					6.4	38.3	34	10.6		2.1				4.3	4.3
	Cat	5.9	0.1–28.7						47.1	47.1								5.9
Trimethoprim-sulfamethoxazole	Horse	13.2	5.5–25.3							50.9	30.2	3.8	1.9	1.9	3.8	7.5
	Dog	6.4	1.3–17.5						2.1	44.7	38.3	4.3	4.3	4.3	2.1
	Cat	0	0.0–19.5					5.9	5.9	52.9	35.3

^a Among horse isolates, SSTI n = 53; dog isolates SSTI n = 42, UTI = 5; cat isolates SSTI n = 15, UTI n = 2.

^b Unshaded areas show the dilution range for each drug.

Vertical solid lines indicate veterinary specific breakpoints.

Double vertical solid lines indicate human interpretative criteria.

ECOFFs are indicated as vertical dotted lines.

Resistance to CVN, FOX, CRE, CEF and OXA after confirmation of methicillin resistance status is presented in S2 Table.

Table 3. MIC distribution and frequency of resistance (%R) among clinical Staphylococcus aureus isolated from horses (n = 53), dogs (n = 47), and cats (n = 17) in Australiab.

Table 3. MIC distribution and frequency of resistance (%R) among clinical Staphylococcus aureus isolated from horses (n = 53), dogs (n = 47), and cats (n = 17) in Australia^b.